Related Experiment Video
Updated: Jul 19, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
Published on: August 8, 2025
Segmental haemangiomas of infancy: A review of 14 cases
Tai Anh Phan1, Susan Adams, Orli Wargon
1Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Insights
Segmental infantile haemangiomas often cause complications. Early corticosteroid treatment can help, but requires careful monitoring for side effects and multidisciplinary team involvement.
Area of Science:
- Pediatric Oncology
- Dermatology
Background:
- Infantile haemangiomas are common benign childhood tumors.
- Segmental subtype is associated with higher complication rates and poorer prognosis.
Observation:
- A retrospective case series of 14 infants with segmental haemangiomas was conducted.
- 71% of infants experienced at least one complication.
Findings:
- Systemic corticosteroids halted growth and reduced pain/ulceration in treated infants.
- High incidence of side effects with corticosteroids: hypertension (40%), cushingoid features (40%), growth suppression (67%).
Implications:
- Early recognition and treatment of segmental haemangiomas can reduce morbidity.
- Multidisciplinary team involvement is crucial for managing associated syndromes and treatment complications.
Abstract:
Haemangiomas of infancy are the commonest benign tumour in childhood, with the majority being a localized subtype, only requiring therapy in specific locations. The segmental subtype, however, confers a higher complication rate, an association with the PHACE syndrome and poorer prognosis. This retrospective case series of 14 infants with segmental haemangiomas aimed to further define the variety of clinical presentations, complication rates, and response to treatment in this subset of patients. We found in our series that 71% of infants with segmental haemangiomas develop at least one complication related to the lesion. Systemic corticosteroids prevented the further growth as well as reduced the pain and ulceration of the segmental haemangiomas in all of those treated. Early recognition and early treatment to arrest the growth of segmental haemangiomas will reduce morbidity and complications associated with these haemangiomas. Corticosteroid use, however, needs to be considered against the high incidence of side-effects such as secondary hypertension (40%), cushingoid features (40%) and growth suppression (67%). In our experience, these infants benefit from multidisciplinary team involvement for the assessment of associated syndromes, and to follow up and avoid complications associated with systemic therapy.